Fig. 1 · Structure

Documents & Downloads

Doramectin

Cat. No. A11385 CAS 117704-25-3
Doramectin is an antiparasitic agent.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Doramectin Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Doramectin from 2 published references. In vitro models include NTS.

Doramectin In Vitro Studies

In adult worms exposed to Doramectin, the IC50 was 16.92 μM at 4 hours post-exposure. NTS incubated with Doramectin at 10 μM scored ≤ 0.5 on the viability scale assessing morphology and motility at 72 hours post-exposure. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Doramectin activity in adult worms

Cell-based study · adult worm [1]

Doramectin: 16.92 μM at 4 hours post-exposure.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IC50 valuesIC50 4 hours post-exposure: 16.92 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
33.33, 11.11, 3.70, 1.43 and 0.41 μM
Exposure duration
4 hours post-exposure
Method
post-drug incubation
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: Doramectin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Compounds and Media (S2); Materials and Methods > In Vitro Drug Sensitivity Assay on Schistosoma mansoni Adult Worms (S21); Materials and Methods > Statistics (S33); Results > In Vitro Activity on NTS and Adult S. mansoni (S47)

IC50 values: IC50 values; comparator: control-well viability scores — Results > In Vitro Activity on NTS and Adult S. mansoni (S47)

Doramectin effects on NTS viability

Cell-based study · NTS [1]

NTS were incubated with Doramectin at 10 μM in culture medium. At 72 hours post-exposure, NTS scored ≤ 0.5 on the viability scale assessing morphology and motility.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
morphology and motility of the NTSReported result 10 μM: NTS scored ≤ 0.5 on our viability scale at 72 hours post-exposure.[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
72 hours post-exposure
Method
incubated in culture medium and the test compounds
Vehicle
DMSO
Reported limits
Removed after verification: value.
Methods and source locations

Compound reported in the paper: Doramectin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Compounds and Media (S2); Materials and Methods > Schistosoma mansoni Larval In Vitro Assay (S12, S13); Materials and Methods > Statistics (S33); Table 1 legend (S64); Table 1 (T1.r4)

morphology and motility of the NTS: morphology and motility of the NTS; comparator: control-well viability scores — Materials and Methods > Schistosoma mansoni Larval In Vitro Assay (S13); Table 1 legend (S64); Table 1 (T1.r4)

Doramectin In Vivo Studies

Female BALB/c mice in a design involving C6 cells received Doramectin intraperitoneally at 14 mg/kg/day for 24 days. LC3I/LC3II protein was significantly elevated in DRM-treated mice compared with the control mice. [2]

Doramectin and LC3I/LC3II protein in mice

Animal study · female BALB/c mice; C6 cells [2]

Female BALB/c mice in a design involving C6 cells received Doramectin intraperitoneally at 14 mg/kg/day for 24 days. LC3I/LC3II protein was significantly elevated in DRM-treated mice compared with the control mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LC3I/LC3II proteinReported result 14 mg/kg/day DRM in 100 µl for 24 days: the LC3I/LC3II protein was significantly elevated in DRM-treated mice compared with the control mice.[2]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
daily; for 24 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Doramectin 14 mg/kg/day DRM in 100 µlsaline (100 µl; control group)14 mg/kg/day DRM in 100 µl for 24 days: the LC3I/LC3II protein was significantly elevated in DRM-treated mice compared with the control mice.[2]
Doramectin 14 mg/kg/day DRM in 100 µl
Model: female BALB/c mice; C6 cells
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Doramectin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animal models (S122, S123, S124, S125); Results > DRM-induced autophagy promotes apoptosis in vivo (S220); Figure 10 legend (S291)

LC3I/LC3II protein: LC3I/LC3II protein; comparator: saline (100 µl; control group) — Materials and methods > Animal models (S124); Results > DRM-induced autophagy promotes apoptosis in vivo (S220)

Doramectin 14 mg/kg/day DRM in 100 µl · Materials and methods > Animal models (S124, S125); Results > DRM-induced autophagy promotes apoptosis in vivo (S220)

Specifications

Manufacturer Adooq Bioscience
CAS Number 117704-25-3
Formula C50H74O14
Molecular Weight 899.11
SMILES
CO[C@@H]1[C@@H](O[C@]2([H])O[C@@H](C)[C@H](O)[C@@H](OC)C2)[C@H](C)O[C@@]([H])(O[C@H](/C(C)=C/C[C@]3([H])C[C@]([H])(OC4=O)C[C@]5(C=C[C@H](C)[C@@H](C6CCCCC6)O5)O3)[C@@H](C)/C=C/C=C7CO[C@@]8([H])[C@]\7(O)[C@@]4([H])C=C(C)[C@H]8O)C1

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 87 mg/mL (96.76 mM)
Ethanol <1 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Doramectin Research References

  1. [1] Panic G, Vargas M, Scandale I, et al. Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni. PLoS Negl Trop Dis (2015). PMID: 26230921 DOI: 10.1371/journal.pntd.0003962 Source material
  2. [2] Chen C, Liang H, Qin R, et al. Doramectin inhibits glioblastoma cell survival via regulation of autophagy in vitro and in vivo. Int J Oncol (2022). PMID: 35137919 DOI: 10.3892/ijo.2022.5319 Source material

Added to your cart

View Cart Checkout
Loading...